Literature DB >> 14527772

In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance.

Anna Marchese1, Laura Gualco, Eugenio A Debbia, Gian Carlo Schito, Anna Maria Schito.   

Abstract

The aim of this study was to reassess the activity of fosfomycin against recently isolated uropathogens circulating in Italy and to evaluate the effect of fosfomycin resistance on the expression of several virulence traits using the rare mutant strains. In vitro activity of fosfomycin was evaluated using 441 Gram-negative organisms isolated from patients with uncomplicated urinary tract infections (UTIs). Fosfomycin was the most active antibiotic against Escherichia coli (99% susceptibility). The activity against Proteus mirabilis was more potent than that of co-trimoxazole and nitrofurantoin (87.5, 67 and 0% susceptibility, respectively). The other microorganisms, accounting for about 7% of all pathogens tested, showed variable susceptibilities to fosfomycin. Compared with susceptible strains, fosfomycin-resistant mutants showed a reduced rate of growth and were impaired in their ability to adhere to uroepithelial cells and to urinary catheters. They were also more resistant to UV irradiation and to phage T7 and showed diminished rates of colicin synthesis and transfer of plasmids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527772     DOI: 10.1016/s0924-8579(03)00230-9

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  21 in total

1.  Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.

Authors:  Alejandro Couce; Alejandra Briales; Alexandro Rodríguez-Rojas; Coloma Costas; Alvaro Pascual; Jesús Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

2.  Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.

Authors:  Robert Sauermann; Rudolf Karch; Herbert Langenberger; Joachim Kettenbach; Bernhard Mayer-Helm; Martina Petsch; Claudia Wagner; Thomas Sautner; Rainer Gattringer; Georgios Karanikas; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

5.  Role of the CpxAR two-component signal transduction system in control of fosfomycin resistance and carbon substrate uptake.

Authors:  Kumiko Kurabayashi; Yuko Hirakawa; Koichi Tanimoto; Haruyoshi Tomita; Hidetada Hirakawa
Journal:  J Bacteriol       Date:  2013-10-25       Impact factor: 3.490

Review 6.  Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 7.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

8.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

9.  Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.

Authors:  Wolfgang Poeppl; Tilman Lingscheid; Dominik Bernitzky; Uwe Y Schwarze; Oliver Donath; Thomas Perkmann; Nicolas Kozakowski; Roberto Plasenzotti; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

10.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.